

WP1066

Catalog No: tcsc2736



Available Sizes

Size: 10mg

Size: 50mg



Specifications

CAS No:

857064-38-1

Formula:

$C_{17}H_{14}BrN_3O$

Pathway:

Epigenetics;Stem Cell/Wnt;JAK/STAT Signaling;JAK/STAT Signaling;Stem Cell/Wnt

Target:

JAK;JAK;JAK;STAT;STAT

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 44 mg/mL (123.52 mM)

Observed Molecular Weight:

356.22

Product Description


WP1066 is a novel inhibitor of **JAK2** and **STAT3**, and also shows effect on STAT5 and ERK1/2, without affecting JAK1 and JAK3.

IC50 & Target: JAK2, STAT3^[1]

In Vitro: WP1066 markedly inhibits the growth of HEL cells in a dose-dependent manner. The IC₅₀ value for inhibition of the proliferation of HEL cells is 2.3 μ M. WP1066 inhibits the growth of human HEL cells carrying the JAK2 V617F mutant isoform^[1].

Blockade of p-STAT3 with WP1066 enhances the cytotoxic effects of CTX on the tumor. The IC₅₀ doses of WP1066 for B16 cells is 2.43 μ M (0.865 μ g/mL)^[2]. WP1066 inhibits AML blast colony-forming cell proliferation, suppresses normal BM progenitor proliferation at increased concentrations, and inhibits AML colony-forming cell proliferation^[3].

In Vivo: WP1066 (30 mg/kg, o.g.) does not further enhance the therapeutic effects of cyclophosphamide on pulmonary melanoma lesions, enhance the therapeutic effects of cyclophosphamide against CNS melanoma, or further enhance immune-mediated cytotoxic effects of CTX in C57BL/6J mice. WP1066 exerts an additive effect to CTX inhibition of the p-STAT3 pathway within the tumor microenvironment^[2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!